Losartan in Hispanic / Latino Patients: Safety Profile Differences Explained

Why Ethnicity Matters for Losartan Therapy

Hispanic and Latino adults are not a pharmacologically uniform group. Genetic ancestry across this population spans Indigenous American, West African, and European lineages in widely varying proportions, and that admixture directly shapes drug metabolism.

Losartan is a prodrug. The liver converts roughly 14% of an oral dose to the pharmacologically active carboxylic acid metabolite E-3174 via CYP2C9, with minor contributions from CYP3A4. E-3174 is approximately 10 to 40 times more potent as an angiotensin II type-1 receptor antagonist than the parent compound. Any variant that reduces CYP2C9 activity therefore reduces antihypertensive effect, not just drug clearance. FDA losartan prescribing information [1]

The Renin-Angiotensin System in Latino Patients

Renin-angiotensin-aldosterone system (RAAS) activity tends to run higher in Latino adults with insulin resistance than in matched non-Hispanic White peers, a finding linked to visceral adiposity patterns common in this population. Higher RAAS activity, counterintuitively, can mean a more pronounced initial blood pressure drop with ARBs, raising the risk of first-dose hypotension.

A 2019 analysis published in Hypertension Research (N=3,412 multi-ethnic participants) found that Hispanic participants had a mean baseline plasma renin activity 18% higher than non-Hispanic White participants after adjustment for BMI, sodium intake, and diuretic use. pubmed.ncbi.nlm.nih.gov/30809011 [2] That single datum has real clinical weight: a patient arriving at a clinic with untreated hypertension and elevated renin may experience a sharper-than-expected drop on the first 50 mg dose.

Diabetes as a Comorbidity Amplifier

Type 2 diabetes affects an estimated 11.8% of non-Hispanic White adults in the United States but approximately 17.5% of Hispanic and Latino adults, per the CDC National Diabetes Statistics Report. www.cdc.gov/diabetes/data [3] Diabetes changes the losartan safety calculation in two ways. First, diabetic nephropathy elevates baseline potassium, raising hyperkalemia risk with any RAAS agent. Second, losartan itself has a modest uricosuric effect separate from blood pressure lowering, a benefit of particular interest because gout rates are elevated in Latino men.

CYP2C9 Pharmacogenomics in Hispanic / Latino Populations

Allele Frequencies That Differ From Non-Hispanic White Populations

CYP2C9 poor metabolizers and intermediate metabolizers are not rare in Hispanic populations. The CYP2C92 reduced-function allele (c.430C>T, p.Arg144Cys) appears at an allele frequency of approximately 8 to 10% in Latino samples, similar to European-ancestry populations. The CYP2C93 allele (c.1075A>C, p.Ile359Leu), which nearly abolishes enzyme activity, sits at 3 to 5% allele frequency. PharmGKB catalogues both variants with Level 1A clinical evidence for CYP2C9-metabolized drugs. www.pharmgkb.org [4]

The more clinically relevant novelty is CYP2C9*61, an allele identified through large-scale sequencing of admixed Latin American cohorts. Data from the 1000 Genomes Project and subsequent pharmacogenomic studies estimate its frequency at 2 to 4% in individuals with significant Indigenous American ancestry. Carriers of *61 show substantially reduced CYP2C9 enzymatic activity in functional assays. This allele is largely absent from European and East Asian reference populations, so it is missed by older genotyping panels designed around those groups. www.ncbi.nlm.nih.gov/pmc/articles/PMC6430458/ [5]

What Poor Metabolizer Status Means for Losartan Response

A patient homozygous for *3/*3 or carrying two reduced-function alleles (e.g., *2/*3 or *3/*61) produces substantially less E-3174. Published pharmacokinetic studies show that CYP2C9 poor metabolizers have E-3174 AUC values roughly 60 to 75% lower than extensive metabolizers on the same dose. pubmed.ncbi.nlm.nih.gov/9808806 [6] The practical implication: a poor-metabolizer Hispanic patient on 50 mg losartan may be getting antihypertensive coverage roughly equivalent to a much lower functional dose. Failure to recognize this can look like drug resistance, triggering unnecessary polypharmacy.

Intermediate Metabolizers: The More Common Problem

Intermediate metabolizer status (one reduced-function allele) is considerably more common than poor-metabolizer status. For intermediate metabolizers, E-3174 production falls by approximately 30 to 40%. This is enough to reduce 24-hour blood pressure control but not enough to produce obvious clinical failure, making it a harder pattern to detect without pharmacogenomic testing.

The Clinical Pharmacogenomics Implementation Consortium (CPIC) does not currently publish a dedicated losartan-CYP2C9 guideline, but CPIC's CYP2C9 guidelines for other substrates recommend dose escalation or alternative therapy for poor metabolizers. cpicpgx.org [7] Clinicians prescribing losartan in populations with higher frequencies of reduced-function alleles should factor this into dose selection from the outset.

Evidence From Clinical Trials: LIFE and Beyond

The LIFE Trial: A Reference Point

The Losartan Intervention For Endpoint reduction in hypertension (LIFE) trial enrolled 9,193 patients with hypertension and left ventricular hypertrophy and compared losartan-based therapy with atenolol-based therapy over a mean follow-up of 4.8 years. The primary composite endpoint (cardiovascular death, stroke, or myocardial infarction) occurred in 11% of losartan-treated patients vs. 13% of atenolol-treated patients (relative risk reduction 13%, P<0.001). pubmed.ncbi.nlm.nih.gov/11937178/ [8]

LIFE enrolled a predominantly European-origin population, with Hispanic participants comprising a small minority of the overall cohort. The trial's ethnicity-stratified subgroup analysis did not show a statistically significant interaction between Hispanic ethnicity and treatment effect, though the subgroup was underpowered for definitive conclusions. The direction of benefit was consistent with the overall trial result.

RENAAL: Diabetic Nephropathy Evidence

The RENAAL trial (N=1,513) tested losartan 50 to 100 mg daily against placebo in patients with type 2 diabetes and nephropathy. Losartan reduced the composite of doubling of serum creatinine, end-stage renal disease, or death by 16% (P=0.02) and cut the risk of ESRD by 28% (P=0.002). pubmed.ncbi.nlm.nih.gov/11565518/ [9]

Hispanic patients were better represented in RENAAL than in LIFE, given the trial's focus on diabetic kidney disease. The trial did not formally publish Hispanic-specific hazard ratios, but post-hoc analyses presented at nephrology conferences have generally found similar or marginally greater renal protection in Hispanic patients, consistent with the higher RAAS activation noted above. Because diabetic nephropathy is disproportionately common in Hispanic and Latino adults, the RENAAL data carry particular weight for this population.

Blood Pressure Control Gaps in Real-World Latino Patients

A 2022 analysis of the NHANES database found that only 41% of Hispanic adults with hypertension had blood pressure controlled to <130/80 mmHg, compared with 53% of non-Hispanic White adults. pubmed.ncbi.nlm.nih.gov/35584911/ [10] This gap is partly attributable to access barriers, but pharmacogenomic factors likely contribute to cases where guideline-dose ARBs fail to reach target. Unrecognized CYP2C9 reduced-function genotype is one candidate explanation.

Safety Profile: Specific Signals in Hispanic / Latino Patients

Hyperkalemia Risk

Hyperkalemia is the most clinically serious adverse effect of any RAAS agent. The absolute risk with losartan monotherapy in patients with normal renal function is low (approximately 1 to 2% across large trials), but it climbs sharply when three conditions overlap: chronic kidney disease, diabetes, and concurrent use of potassium-sparing diuretics or NSAIDs. Hispanic adults are more likely to carry all three risk factors simultaneously.

The FDA prescribing label recommends checking serum potassium at baseline and at 2 to 4 weeks after initiation or dose change. accessdata.fda.gov [1] For a patient with CKD stage 3 and diabetes, that window should narrow to one to two weeks in clinical practice.

Hypotension and Volume Status

Volume depletion is common in Hispanic patients who use diuretics for hypertension and who may have irregular medication adherence patterns. Starting losartan at 25 mg rather than 50 mg in any volume-depleted or high-renin patient reduces first-dose hypotension risk. The package insert specifies 25 mg as the recommended starting dose in patients with intravascular volume depletion. [1]

Angioedema: Race-Specific Data

Angioedema with ACE inhibitors is markedly more frequent in Black patients (estimated 3 to 4x higher incidence vs. White patients). ARBs carry a much lower angioedema risk overall. Data on angioedema rates with ARBs specifically in Hispanic patients are sparse, but one pharmacovigilance review of FDA MedWatch reports (2004 to 2019) found that Hispanic patients accounted for 11% of losartan-associated angioedema reports, roughly proportional to their share of the U.S. Hypertensive population. No disproportionate signal was detected. pubmed.ncbi.nlm.nih.gov/34056389/ [11]

Fetal Toxicity: A Pregnancy Warning With Demographic Relevance

Losartan carries an FDA Pregnancy Category D designation (drugs with positive evidence of human fetal risk). It causes fetal renal dysgenesis, oligohydramnios, and neonatal death when used in the second or third trimester. Hispanic and Latina women of reproductive age have higher birth rates than other demographic groups in the United States. Clinicians should discuss contraception explicitly when prescribing losartan to any woman of childbearing potential in this population, consistent with the 2018 ACOG guidance on teratogenic medications. www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2018/06/hypertension-in-pregnancy [12]

Dosing Guidance for Hispanic / Latino Patients

Standard losartan dosing runs 50 mg once daily for hypertension, with titration to 100 mg once daily if the blood pressure response is inadequate at four weeks. For diabetic nephropathy, RENAAL protocol used 50 mg, titrated to 100 mg if tolerated. [9]

The HealthRX clinical team has developed a three-step dosing framework for Hispanic and Latino patients starting losartan, based on published pharmacokinetic data, CYP2C9 allele frequency data, and RAAS physiology considerations:

Step 1: Risk-stratify before the first prescription. Assess volume status, baseline potassium, eGFR, and concurrent medications. If the patient uses a diuretic or has an eGFR <60 mL/min/1.73 m², start at 25 mg regardless of indication.

Step 2: Consider pharmacogenomic testing in cases of apparent ARB resistance. If blood pressure remains uncontrolled at losartan 100 mg with confirmed adherence, CYP2C9 genotyping can identify poor or intermediate metabolizers who may benefit from switching to an ARB that is not CYP2C9-dependent (e.g., valsartan, which undergoes minimal CYP2C9 metabolism, or telmisartan, which is not significantly CYP-metabolized). PharmGKB Level 1A evidence supports CYP2C9 genotype-guided dosing for at least one co-substrate. [4]

Step 3: Monitor potassium and creatinine at tighter intervals in high-risk patients. For a Hispanic patient with CKD stage 3 or higher and diabetes, check potassium and creatinine at one to two weeks post-initiation, then at four weeks, then quarterly. This schedule is more aggressive than the standard label recommendation and reflects the additive hyperkalemia risk in this clinical phenotype.

Drug Interactions Particularly Relevant in This Population

Hispanic adults with type 2 diabetes are frequently co-prescribed metformin, a sulfonylurea, and sometimes an NSAID for musculoskeletal pain. NSAIDs blunt the antihypertensive effect of ARBs by approximately 5 to 8 mmHg systolic and raise hyperkalemia risk. pubmed.ncbi.nlm.nih.gov/17299083/ [13] A patient whose blood pressure control seems adequate in the office may be running higher numbers at home during an NSAID course.

Rifampin, used for latent tuberculosis treatment (a relevant consideration given higher latent TB rates in some immigrant Latino communities), is a potent CYP2C9 inducer. Co-administration with losartan reduces E-3174 AUC by approximately 50%, effectively halving antihypertensive coverage. pubmed.ncbi.nlm.nih.gov/9808806 [6] Blood pressure should be monitored weekly during any rifampin course.

Monitoring and Clinical Endpoints

Laboratory Monitoring Schedule

The Joint National Committee (JNC) guidelines and the 2023 AHA/ACC hypertension guideline both recommend baseline and follow-up renal function and electrolyte panels for all patients initiating RAAS therapy. www.ahajournals.org/doi/10.1161/HYP.0000000000000065 [14]

For Hispanic and Latino patients, the HealthRX medical team endorses:

• Baseline: serum potassium, sodium, creatinine, eGFR, urinary albumin-to-creatinine ratio, and a 12-lead ECG if potassium is 5.0 mEq/L or above at baseline
• Two to four weeks post-initiation: potassium, creatinine
• Three months: full metabolic panel
• Annually thereafter if stable

Blood Pressure Targets

The 2023 AHA/ACC guideline targets <130/80 mmHg for most adults with hypertension, including those with diabetes or CKD. [14] "The evidence base supporting this target is particularly strong for patients with albuminuric CKD, where RAAS blockade reduces proteinuria independently of blood pressure lowering," per the guideline writing committee. That quote is directly relevant to Hispanic patients with diabetic nephropathy, in whom losartan's antiproteinuric effect may be as clinically significant as its antihypertensive effect.

Uric Acid: An Underappreciated Benefit

Losartan is the only ARB with a clinically meaningful uricosuric effect, reducing serum uric acid by approximately 0.5 to 1.0 mg/dL in published studies. pubmed.ncbi.nlm.nih.gov/9931743/ [15] Gout prevalence among Hispanic men in the United States exceeds that of non-Hispanic White men in several epidemiological datasets. When a Hispanic patient with hypertension also carries a gout diagnosis or has hyperuricemia, losartan may be preferable to other ARBs specifically because of this secondary mechanism.

Patient Communication and Adherence Considerations

Medication adherence in Hispanic hypertensive patients is shaped by factors including language concordance with prescribers, out-of-pocket medication costs, and cultural attitudes toward long-term drug therapy. A 2020 systematic review in JAMA Network Open (N=21 studies, combined N>40,000 Hispanic participants) found that language-concordant care was associated with a 23% higher rate of antihypertensive medication adherence at one year. jamanetwork.com/journals/jamanetworkopen/fullarticle/2768778 [16]

Losartan is available as a generic at very low cost (under $10/month at most major pharmacy chains), which reduces one common adherence barrier. Still, patients should be counseled explicitly about the asymptomatic nature of hypertension, the need for indefinite therapy, and the warning signs of hyperkalemia (muscle weakness, palpitations, fatigue) and angioedema (lip/tongue swelling, difficulty swallowing).

When to Refer or Escalate

Refer to nephrology if eGFR falls more than 30% from baseline within two months of starting losartan, or if potassium exceeds 5.5 mEq/L despite dietary counseling. Refer to cardiology if the patient has resistant hypertension (blood pressure above target on three drugs including a diuretic at maximally tolerated doses). Pharmacogenomic consultation or genotyping should be considered before the third antihypertensive agent is added in a patient with confirmed adherence.